Human Cell Line Activation Test (h-CLAT)

OECD 442E - In Vitro Sensitization Test

Contact for Quotation Now

Assay Overview

The h-CLAT test method is an in vitro toxicology assay that evaluates cell surface marker expression - CD86 and CD54 on THP-1 cells, a human monocytic leukemia cell line following a 24 hrs exposure to a test substance. CD86 and CD54 are surface molecules that are typical markers of Dendritric Cell (DC) activation and play an important role in T cell priming. Cell surface marker expression is measured by flow cytometry following fluorescent staining with fluorochrome-tagged antibodies. Assessment of surface markers expression at sub-cytotoxic concentrations is also assessed concurrently. The relative fluorescence intensity of the surface markers is calculated by comparing results to vehicle control are calculated and used in the h-CLAT prediction model, allowing for discrimination between sensitizers and non-sensitizers.

Regulatory Acceptance

OECD Test Guideline 442E has been approved for use as of 9 October 2017. Previously, the h-CLAT has been evaluated in a European Union Reference Laboratory for Alternatives to Animal Testing (EURL-ECVAM) and was considered scientifically valid to be used as part of an intergrated approach to testing and assessment (IATA) for discrimination between sensitizers and non-sensitizers for hazard classification and labelling.

The h-CLAT for Assessment of Dermal Sensitization Potency of Commercially Available Mixtures and the OECD Proficiency Chemicals

-PDF Poster, 10th World Congress.

Pitfalls, Issues and Remediation- Human Cell Line Activation
(h-CLAT) In Vitro Sensitization

OECD 442E: h-CLAT now offered at MB Research Labs

In Vitro Sensitization Integrated Testing Strategy

MB Research has developed a non-animal Integrated Testing Strategy (ITS) for chemical-induced contact hypersensitivity (skin sensitization). This ITS provides a completely non-animal alternative to traditional testing methods. Together, our three assays address three key events on the skin sensitization adverse outcome pathway (AOP).